November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Abemaciclib/Fulvestrant Demonstrates OS Benefit in HR+/HER2- Breast Cancer
July 30th 2019The combination of abemaciclib and fulvestrant has demonstrated a statistically significant improvement in overall survival compared with fulvestrant and placebo in women with HR–positive, HER2-negative advanced or metastatic breast cancer who have previously received endocrine therapy, according to updated interim results from the phase III MONARCH 2 trial.
Read More
Pembrolizumab and Chemotherapy Met Primary Endpoint in Phase III TNBC Trial
July 29th 2019The combination of pembrolizumab with chemotherapy demonstrated a benefit in terms of pathological complete response when used as neoadjuvant therapy compared with chemotherapy alone in patients with triple-negative breast cancer, according to interim results of the pivotal phase III KEYNOTE-522 trial.
Read More
Health Canada Approves Extended Adjuvant Neratinib for Early-Stage HR+ Breast Cancer
July 23rd 2019Neratinib has received approval from Health Canada for the treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer in the extended adjuvant setting. The agent should be given to patients 1 year after completing trastuzumab-based adjuvant therapy.<br />
Read More
Meisel Reviews Systemic Therapies for Breast Cancer With 2 Case Studies
July 17th 2019Jane Lowe Meisel, MD, reviewed systemic therapy options for treating patients with breast cancer with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion. Meisel explained the treatment considerations she makes for treating patients with breast cancer during the dinner event in terms of 2 case studies.
Read More
Encouraging SOLAR-1 Trial Results Lead to Alpelisib Approval
July 8th 2019The SOLAR-1 findings were presented during a satellite symposium at the 2019 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany. The trial demonstrated the role of <em>PIK3CA </em>as a predictive marker for alpelisib’s clinical efficacy, said Peter A. Fasching, MD, associate professor of gynecology and obstetrics at Friedrich-Alexander University of Erlangen-Nuremberg in Germany, during the symposium.
Read More
Tolerability Improves With Prophylactic Strategies for Adjuvant Neratinib in HER2+ Breast Cancer
July 8th 2019Preventive strategies for severe diarrhea associated with adjuvant treatment with neratinib improved tolerability for the agent when patients received budesonide or colestipol-with-loperamide prophylaxis, according to findings from the CONTROL study.
Read More
With Biomarker Expansion, Combinations and Personalized Medicine Continue to Rise
July 5th 2019Biomarker expansion has enjoyed a boom since 2006, with patient incidence of positive biomarkers reaching up to 50% in non–small cell lung cancer and melanoma and 25% in acute myeloid leukemia and myelodysplastic syndromes, according to the <em>Global Oncology Trends 2018</em> report.
Read More
Patients With MBC Have Reduced Toxicity Burden With Dual HER2-Targeted Therapy in the Front Line
July 4th 2019Patients with HER2-positive metastatic breast cancer receiving frontline HER2-targeted therapy with pertuzumab and trastuzumab followed by T-DM1 in the second-line setting may be able to forgo chemotherapy without increasing the risk of early death, according to results from the phase II PERNETTA trial.
Read More
Explaining PFS2 in the MONALEESA-7 Trial for HR+/HER2- Breast Cancer
July 3rd 2019Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.
Watch